FR2482861B1 - - Google Patents

Info

Publication number
FR2482861B1
FR2482861B1 FR8110140A FR8110140A FR2482861B1 FR 2482861 B1 FR2482861 B1 FR 2482861B1 FR 8110140 A FR8110140 A FR 8110140A FR 8110140 A FR8110140 A FR 8110140A FR 2482861 B1 FR2482861 B1 FR 2482861B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8110140A
Other languages
French (fr)
Other versions
FR2482861A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of FR2482861A1 publication Critical patent/FR2482861A1/fr
Application granted granted Critical
Publication of FR2482861B1 publication Critical patent/FR2482861B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/822—Identified hapten
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/823—Immunogenic carrier or carrier per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR8110140A 1980-05-21 1981-05-21 Procede de preparation d'un antigene et d'un anticorps du glucagon intestinal Granted FR2482861A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6804080A JPS56163456A (en) 1980-05-21 1980-05-21 Preparation of antigen

Publications (2)

Publication Number Publication Date
FR2482861A1 FR2482861A1 (fr) 1981-11-27
FR2482861B1 true FR2482861B1 (esLanguage) 1983-09-09

Family

ID=13362282

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8110140A Granted FR2482861A1 (fr) 1980-05-21 1981-05-21 Procede de preparation d'un antigene et d'un anticorps du glucagon intestinal

Country Status (8)

Country Link
US (1) US4407965A (esLanguage)
JP (1) JPS56163456A (esLanguage)
BE (1) BE888906A (esLanguage)
DE (1) DE3120312C2 (esLanguage)
DK (1) DK159163C (esLanguage)
FR (1) FR2482861A1 (esLanguage)
GB (1) GB2079289B (esLanguage)
SE (1) SE454301B (esLanguage)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1249395A (en) * 1982-09-30 1989-01-24 Tetsuya Tachikawa Human leukemia virus-related peptides, a process for production thereof, antibodies of the peptides and a process for production of the antibodies
CA1256795A (en) * 1983-12-28 1989-07-04 Dennis A. Carson Anti-idiotype antibodies induced by synthetic polypeptides
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US5116725A (en) * 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
US4654419A (en) * 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
EP0196319B1 (en) * 1984-09-19 1992-01-02 The Regents Of The University Of California Retroviral polypeptides associated with human cellular transformation
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0792458B2 (ja) * 1986-03-14 1995-10-09 郁男 山科 糖鎖特異抗体アツセイプレ−ト及びその製造方法
US5202270A (en) * 1986-05-15 1993-04-13 Abbott Laboratories Cocaine and cocaine metabolites assay tracers, immunogens and antibodies
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
BR112017005110A2 (pt) 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
CA3034777A1 (en) 2016-08-30 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
MX2020002057A (es) 2017-08-22 2020-07-13 Regeneron Pharma Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) * 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) * 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives

Also Published As

Publication number Publication date
SE8103198L (sv) 1981-11-22
DK159163B (da) 1990-09-10
JPS56163456A (en) 1981-12-16
DK222081A (da) 1981-11-22
DE3120312A1 (de) 1982-03-04
DE3120312C2 (de) 1985-08-29
JPS6223822B2 (esLanguage) 1987-05-25
FR2482861A1 (fr) 1981-11-27
US4407965A (en) 1983-10-04
GB2079289B (en) 1983-10-26
BE888906A (fr) 1981-11-23
DK159163C (da) 1991-02-11
GB2079289A (en) 1982-01-20
SE454301B (sv) 1988-04-18

Similar Documents

Publication Publication Date Title
FR2496567B3 (esLanguage)
GR78326B (esLanguage)
FR2482861B1 (esLanguage)
FR2485189B1 (esLanguage)
IN153895B (esLanguage)
FR2496602B1 (esLanguage)
GR74514B (esLanguage)
FR2492659B3 (esLanguage)
FR2481425B1 (esLanguage)
FR2496637B1 (esLanguage)
FR2490952B3 (esLanguage)
GR74688B (esLanguage)
FR2491458B1 (esLanguage)
FR2476553B1 (esLanguage)
GR74941B (esLanguage)
JPS56109696U (esLanguage)
FR2477717B1 (esLanguage)
JPS56116755U (esLanguage)
JPS56111268U (esLanguage)
JPS56110135U (esLanguage)
FR2488485B3 (esLanguage)
FR2494410B1 (esLanguage)
JPS56103887U (esLanguage)
JPS56110622U (esLanguage)
JPS55134800U (esLanguage)

Legal Events

Date Code Title Description
ST Notification of lapse